CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment